Hepatit B'den D'ye Hep Güncel - page 63

51
17.
Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous
HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection:
implications for antiviral therapy. Gut 2003;52:416—9.
18.
Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg
seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-
27.
19.
Brunetto MR, Olivari F, Colombatto P, et al. Use of hepatitis B surface antigen
serum levels help to distinguish active from inactive hepatitis B virus genotype
D carriers. Gastroenterology 2010;139:483—90.
20. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful
serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e
antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451—
9.
21.
Castéra L, Bernard PH, Le Bail B, et al. Transient elastography and biomarkers
for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
Aliment Pharmacol Ther 2011;33:455—65.
22.
Hadziyannis SJ, Papatheodoridis GV. Hepatitis Be antigen negative chronic
hepatitis B – natural history and treatment. Semin Liver Dis 2006;26:130–41.
23.
Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, et al. Significant
prevalence of histologic disease in patients with chronic hepatitis B and mildly
elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol
2008;6:569—74.
24.
Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigennegative chronic hepatitis
B. Hepatology, 2001;34:617-624
25.
Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-
negative chronic hepatitis B. Semin Liver Dis. 2003;23:81-88.
26.
Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of
interferon-alpha treated and untreated patients with HBeAg-negative chronic
hepatitis B. J Hepatol. 2001;34:306-313.
27.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et
al. Statements from the Taormina expert meeting on occult hepatitis B virus
infection. J Hepatol 2008;49:652–57.
28.
Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in
HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV
reactivation. Transplantation 2005;79:1631–33
Kronik Hepatit B Enfeksiyonunun Dođal Seyri ve Özel Durumlar
1...,53,54,55,56,57,58,59,60,61,62 64,65,66,67,68,69,70,71,72,73,...328